Bristol-Myers Squibb stock holds steady as CAR-T pause and Camzyos data reshape the risk picture
Published on 09/02/2026 at 20:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol-Myers Squibb stock (ISIN US1078421011) is trading around 66.9 USD per share on the New York Stock Exchange as of September 2, 2026, implying a market capitalization in the area of 136.7 billion USD according to a recent price snapshot from IT Boltwise.
Clinical setbacks and CAR-T pause dominate sentiment
In early September 2026, Bristol-Myers Squibb is in the spotlight because multiple clinical trials of CAR-T cell therapies for autoimmune conditions have been paused after reports of inflammatory side effects in recent testing, as summarized by Ground News based on broader coverage. This pause affects studies in which the company is exploring the use of CAR-T technology beyond oncology, and it raises questions about how quickly this high-risk, high-reward area can progress.
For investors, the pause is material because CAR-T programs in autoimmune diseases had been highlighted as a potential long-term growth driver that could complement established oncology franchises and cardiovascular products. A report by Biomednexus that tracks sector moves notes that Bristol-Myers Squibb's ticker BMY traded at 66.81 USD on August 31, 2026, and 66.92 USD on September 1, 2026, a move of 0.2 percent, showing that the immediate price reaction has been relatively subdued despite the clinical headlines.
Camzyos data and cardiovascular portfolio add balance
Alongside the CAR-T issues, new data for the cardiomyopathy therapy Camzyos are drawing attention in early September 2026, according to an IT Boltwise overview that looks at Bristol-Myers Squibb's pipeline and product updates. The article notes that Camzyos data are helping to shift part of the focus back to the cardiovascular segment, which the company sees as a pillar of medium-term growth.
From the perspective of risk balance, investors are weighing the potential of Camzyos against the uncertainty around autoimmune CAR-T. The same IT Boltwise piece indicates that as of September 2, 2026, Bristol-Myers Squibb stock is quoted at about 66.90 USD to 66.91 USD, up roughly 0.7 percent from a previous reference level of 66.47 USD, and that this price level translates into a market capitalization of approximately 136.68 billion USD. The modest gain suggests that, so far, the market is treating the CAR-T pause as a manageable setback rather than a thesis-breaking event.
A separate sector commentary from BioSpace, picked up by NJBIZ in reporting on contract manufacturing group Cellares, illustrates another pipeline-related development: Bristol-Myers Squibb has decided to terminate a 380 million USD manufacturing pact with Cellares, which triggered planned layoffs at the partner. While not directly tied to one specific product, the move underlines that the company is actively reshaping its external manufacturing footprint as pipeline priorities evolve.
More on Bristol-Myers Squibb stock and fundamentals
For additional updates on Bristol-Myers Squibb stock, regulatory news and upcoming results, the topic page at ad-hoc-news.de provides a compact overview of recent headlines linked to the ISIN US1078421011.
Pipeline, approvals and revenue drivers
Even with the recent CAR-T setback, Bristol-Myers Squibb continues to benefit from a portfolio of approved medicines and new indications. A pharmacy bulletin from VativoRx dated September 2, 2026 highlights that on August 6, 2026, the US Food and Drug Administration granted accelerated approval to Tudriqev in combination with Opdivo, Bristol-Myers Squibb's PD-1 inhibitor, for unresectable advanced cutaneous melanoma after progression on prior PD-1-based therapy. The involvement of Opdivo in this new regimen reinforces the central role of immuno-oncology in the company's revenue mix.
Analyst and commentator overviews, such as a September 2, 2026 note on dividend stocks by WallStreetZen, point out that Bristol-Myers Squibb is benefiting from fresh FDA approvals and stronger growth from new drugs in its portfolio. While these commentaries do not always quote exact quarterly numbers, they underline that newer products, including immunology and cardiovascular agents, are increasingly important for revenue as older blockbusters face patent expiration.
Regarding recent fundamental data, the most up-to-date detailed quarterly figures for Bristol-Myers Squibb stem from its latest interim report, which covers a 2026 period within the last nine months. Because the exact revenue and earnings figures for this quarter are not fully visible in the search snippets available in this narrow-day context, investors are relying on company filings and investor-relations presentations for precise values. Historical context from previous fiscal years remains relevant for long-term analysis but does not change the near-term trading picture described here.
Stock price context and options activity
Several stock portals provide a snapshot of Bristol-Myers Squibb's current trading level around the turn of August to September 2026. MarketBeat's options overview for BMY shows a closing common-share price of 66.93 USD on August 31, 2026 at 3:58 PM Eastern, with a small move to 66.90 USD in extended trading as of 08:37 AM Eastern on September 1, 2026. This data confirms that the stock has been oscillating just below 67 USD, with limited volatility.
An AI-based analysis page from AltIndex notes that Bristol-Myers Squibb shares trade at 66.95 USD with a market capitalization of about 138 billion USD. Taken together with the IT Boltwise estimate of 136.68 billion USD at 66.91 USD, these figures show that the market capitalization range of roughly 136.7 to 138.0 billion USD is consistent with the share price in the mid-60 USD zone as of late August and early September 2026.
The MarketBeat options chain page also illustrates that short-dated options around the 67.00 USD and 68.00 USD strikes expiring on September 4, 2026 have meaningful open interest and trade volume. For example, calls at the 67.00 USD strike show open interest of 368 contracts, while calls at 68.00 USD have open interest of 517 contracts, with implied volatility in the high-20 percent range. This pattern suggests that some traders are positioning for modest upside in Bristol-Myers Squibb stock over very short horizons, rather than pricing in extreme moves from the current clinical news.
Representative product: Opdivo underpins oncology and combo strategies
A representative product for Bristol-Myers Squibb's business model is Opdivo, the PD-1 inhibitor nivolumab that has become a backbone of many oncology regimens. As noted in the September 2, 2026 VativoRx bulletin, Opdivo is now approved in combination with the newly authorized oncolytic immunotherapy Tudriqev for advanced cutaneous melanoma after prior PD-1 therapy, which expands its clinical footprint into another niche of skin cancer treatment.
Opdivo's broad label and frequent use in combination therapies make it a key revenue driver. Each new approved combination, such as the August 6, 2026 accelerated approval in melanoma, offers incremental volume and can help offset pricing pressure or competition in other indications. For retail investors, understanding how products like Opdivo link into newer assets and regimens is important for assessing whether Bristol-Myers Squibb can maintain or grow its oncology revenue base in the face of evolving standards of care.
Stock level and investor takeaway
As of the latest available data around September 2, 2026, Bristol-Myers Squibb stock is trading close to 66.90 USD per share on the New York Stock Exchange, with market capitalization estimates between 136.7 billion USD and 138.0 billion USD depending on the precise quotation. Recent price comparisons from August 31, 2026 and September 1, 2026 show moves in the 0.2 to 0.7 percent range, underscoring that the clinical headlines have not triggered abrupt volatility.
Bristol-Myers Squibb key data
- Company: Bristol-Myers Squibb Company
- ISIN: US1078421011
- Ticker: BMY
- Trading venue: New York Stock Exchange
- Price (as of September 2, 2026): 66.90 USD
- Market capitalization: 136.68 billion USD (as of September 2, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
